Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease
Standard
Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. / Neumann, Johannes Tobias; Tzikas, Stergios; Funke-Kaiser, Anne; Wilde, Sandra; Appelbaum, Sebastian; Keller, Till; Ojeda-Echevarria, Francisco; Zeller, Tanja; Zwiener, Isabella; Sinning, Christoph R; Jagodzinski, Annika; Schnabel, Renate B; Lackner, Karl J; Münzel, Thomas; Blankenberg, Stefan; Wild, Philipp S; Sydow, Karsten.
In: ATHEROSCLEROSIS, Vol. 228, No. 2, 06.2013, p. 451-459.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease
AU - Neumann, Johannes Tobias
AU - Tzikas, Stergios
AU - Funke-Kaiser, Anne
AU - Wilde, Sandra
AU - Appelbaum, Sebastian
AU - Keller, Till
AU - Ojeda-Echevarria, Francisco
AU - Zeller, Tanja
AU - Zwiener, Isabella
AU - Sinning, Christoph R
AU - Jagodzinski, Annika
AU - Schnabel, Renate B
AU - Lackner, Karl J
AU - Münzel, Thomas
AU - Blankenberg, Stefan
AU - Wild, Philipp S
AU - Sydow, Karsten
N1 - Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
PY - 2013/6
Y1 - 2013/6
N2 - AIMS AND BACKGROUND: Midregional proadrenomedullin (MR-proADM) is a protein, which exerts various effects on the cardiovascular system. Recent studies underscored its prognostic implications in patients with acute dyspnea and cardiovascular diseases. Therefore, we aimed to determine the distribution of MR-proADM in the general population and to reveal potential associations of MR-proADM with cardiovascular risk factors and measures of subclinical cardiovascular disease.METHODS AND RESULTS: MR-proADM plasma concentrations were determined in individuals of the population-based cohort of the Gutenberg Health Study (N = 5000) using a commercially available fluoroimmunoassay. Individuals were enrolled between April 2007 and October 2008. Subclinical cardiovascular disease was assessed using echocardiographic and functional measures of myocardial and vascular function. The mean age of the study population was 55.5 ± 10.9 years. In the overall population we determined a median MR-proADM plasma concentration of 0.44 nmol/L in men and women. MR-proADM concentrations were elevated in individuals with hypertension, diabetes, dyslipidemia, known cardiovascular disease, heart failure, peripheral artery disease, atrial fibrillation, and history of myocardial infarction and stroke. In men, we observed a positive association of MR-proADM with reduced ejection fraction, intraventricular septal diameter, wall thickness, and echocardiographic measures of diastolic dysfunction.CONCLUSIONS: In this study, we present age-dependent reference values for MR-proADM in a representative population sample. Elevated MR-proADM plasma concentrations were strongly associated with classical cardiovascular risk factors and manifest cardiovascular diseases. Furthermore, we revealed a gender-specific association with echocardiographic measures of hypertension. MR-proADM seems to be a promising prognostic biomarker for subclinical and manifest cardiovascular disease.
AB - AIMS AND BACKGROUND: Midregional proadrenomedullin (MR-proADM) is a protein, which exerts various effects on the cardiovascular system. Recent studies underscored its prognostic implications in patients with acute dyspnea and cardiovascular diseases. Therefore, we aimed to determine the distribution of MR-proADM in the general population and to reveal potential associations of MR-proADM with cardiovascular risk factors and measures of subclinical cardiovascular disease.METHODS AND RESULTS: MR-proADM plasma concentrations were determined in individuals of the population-based cohort of the Gutenberg Health Study (N = 5000) using a commercially available fluoroimmunoassay. Individuals were enrolled between April 2007 and October 2008. Subclinical cardiovascular disease was assessed using echocardiographic and functional measures of myocardial and vascular function. The mean age of the study population was 55.5 ± 10.9 years. In the overall population we determined a median MR-proADM plasma concentration of 0.44 nmol/L in men and women. MR-proADM concentrations were elevated in individuals with hypertension, diabetes, dyslipidemia, known cardiovascular disease, heart failure, peripheral artery disease, atrial fibrillation, and history of myocardial infarction and stroke. In men, we observed a positive association of MR-proADM with reduced ejection fraction, intraventricular septal diameter, wall thickness, and echocardiographic measures of diastolic dysfunction.CONCLUSIONS: In this study, we present age-dependent reference values for MR-proADM in a representative population sample. Elevated MR-proADM plasma concentrations were strongly associated with classical cardiovascular risk factors and manifest cardiovascular diseases. Furthermore, we revealed a gender-specific association with echocardiographic measures of hypertension. MR-proADM seems to be a promising prognostic biomarker for subclinical and manifest cardiovascular disease.
KW - Adrenomedullin/blood
KW - Adult
KW - Age Factors
KW - Aged
KW - Asymptomatic Diseases
KW - Biomarkers/blood
KW - Cardiovascular Diseases/blood
KW - Cross-Sectional Studies
KW - Echocardiography
KW - Female
KW - Fluoroimmunoassay
KW - Germany/epidemiology
KW - Humans
KW - Linear Models
KW - Male
KW - Middle Aged
KW - Peptide Fragments/blood
KW - Phenotype
KW - Predictive Value of Tests
KW - Prevalence
KW - Prognosis
KW - Prospective Studies
KW - Protein Precursors/blood
KW - Risk Assessment
KW - Risk Factors
KW - Sex Factors
KW - Up-Regulation
U2 - 10.1016/j.atherosclerosis.2013.03.006
DO - 10.1016/j.atherosclerosis.2013.03.006
M3 - SCORING: Journal article
C2 - 23562132
VL - 228
SP - 451
EP - 459
JO - ATHEROSCLEROSIS
JF - ATHEROSCLEROSIS
SN - 0021-9150
IS - 2
ER -
